BiotechTube
Scioto Biosciences

Scioto Biosciences

Columbus, United States· Est.
sciotobiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Scioto Biosciences is a private, preclinical-stage biotech pioneering a novel approach to live bacterial therapeutics (LBTs). The company's proprietary Activated Bacterial Therapeutics (ABT) platform aims to overcome key delivery challenges by utilizing bacterial biofilms to enhance persistence and activity in the gastrointestinal tract. Its lead program, SB-121, has completed a Phase Ib trial in Autism Spectrum Disorder (ASD), demonstrating initial clinical validation of its platform. The company is targeting significant unmet medical needs in neurodevelopmental and GI conditions, positioning itself at the intersection of the microbiome and gut-brain axis fields.

Autism Spectrum DisorderGastrointestinal DisordersNeurodevelopmental Disorders

Technology Platform

Activated Bacterial Therapeutics (ABT) platform that pre-activates beneficial bacteria to form biofilms ex vivo, enhancing their survival, persistence, and therapeutic activity in the gastrointestinal tract.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The company is targeting large, underserved markets in autism and GI disorders through a novel microbiome modulation approach.
Success with its lead program could validate its platform for broader application across the gut-brain axis, including other neuropsychiatric and inflammatory conditions.
The growing scientific and investor interest in microbiome therapeutics creates a favorable environment for platform validation and partnership.

Risk Factors

The clinical development path for a live bacterial therapeutic in a complex neurodevelopmental disorder like autism is highly risky and uncertain.
The company's novel biofilm-based delivery platform requires robust clinical proof-of-concept.
As a private, preclinical-stage biotech, it faces significant financing risks and operates in an increasingly competitive microbiome therapeutics landscape.

Competitive Landscape

Scioto operates in the competitive microbiome therapeutics space, competing with other companies developing live biotherapeutic products (LBPs) and engineered probiotics. Key competitors range from large pharma to public biotechs like Seres Therapeutics, Vedanta Biosciences, and Finch Therapeutics. Scioto's differentiation lies in its specific focus on biofilm-enhanced delivery for gut-brain axis indications, a niche but potentially high-impact approach.

More companies in Microbiome Therapeutics →More companies in United States →